Maqui Berry Extract for Osteoblast-Driven Bone Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-osteoporotic drugs inhibit osteoclast activity, leading to suppressed bone remodeling and potential microdamage, while there is a need for treatments that promote new bone formation and enhance bone health, particularly for conditions like congenital bone defects, bone deformations, osteosarcoma, bone dysplasia, osteomalacia, osteogenesis imperfecta, and Paget's disease of the bone.
Innovation Solution
The use of maqui berry extract, enriched with delphinidins, to induce new bone formation and enhance bone repair by promoting osteoblast activity and inhibiting inflammatory pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-osteoporotic drugs (bisphosphonates, anti-RANKL antibodies) are used to inhibit osteoclast activity, then bone resorption is reduced and bone mineral density is improved, but bone remodeling is suppressed and microdamage accumulates leading to fractures
Solution Approach 1:
Instead of continuing to use anti-resorptive drugs that inhibit osteoclast activity, the patent inverts the approach by using maqui berry extract to stimulate osteoblast activity and promote bone formation. This shifts the therapeutic strategy from preventing bone loss to actively promoting bone repair and remodeling, thereby avoiding the harmful accumulation of microdamage while still improving bone density.
Solution Approach 2:
The patent changes the therapeutic parameter from inhibiting osteoclast activity to stimulating osteoblast activity. By administering maqui berry extract containing anthocyanins and flavonoids, the patent modifies the biological parameter of bone cell activity to favor bone formation over bone resorption, thereby resolving the contradiction between improving bone density and preventing microdamage.
2Productivity
If maqui berry extract is used to promote new bone formation, then bone repair and osteoblast activity are enhanced, but the treatment duration and dosage optimization are still under investigation
Solution Approach 1:
The patent performs preliminary actions by conducting both in vitro and in vivo studies to evaluate the efficacy of maqui berry extract on bone formation before clinical application. The in vitro studies on osteoblast cell lines and the in vivo studies on ovariectomized mouse models provide preliminary data on optimal dosage and treatment duration, reducing the uncertainty associated with treatment timeframes.
Data Source
Figure 1
Figure 2/1
Figure 2/2
AI summary
The present invention relates generally to maqui berry for use in the treatment or prevention of bone injuries, diseases or defects, the promotion of healing of bone injuries, and the promotion of bone formation. Particular embodiments as disclosed herein find application in, inter alia, the treatment of bone fractures and in bone formation and regeneration. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing of bone injury or diseases or defects selected from the group of congenital bone defects, bone or spinal deformation, osteosarcoma, bone dysplasia, osteomalacia (rickets), osteogenesis imperfecta (brittle bone disorder), Paget's disease of the bone, osteoarthritis.